Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — 0.00 — — — — —
P/S ratio
— — 3,065.12 — — — — —
Altman Z″-Score (non-manufacturers)
— — 3.50 — — — — —
P/FCF ratio
— — 0.00 — — — — —
P/Operating CF
— — (25.14) — — — — —
P/B ratio
— — 0.00 — — — — —
Price to Tangible BV
— — 0.00 — — — — —
EV/Sales
— — 1,313.57 — — — — —
EV/EBITDA
— — 0.00 — — — — —
EV/Operating CF
— — (6.12) — — — — —
EV/FCF
— — (2.25) — — — — —
Quick Ratio
— 6.26 18.20 10.98 7.96 14.38 14.58 15.75
Current Ratio
— 6.54 18.53 11.22 8.22 15.22 15.76 39.53
Net Debt/EBITDA
— 1.35 7.24 2.97 0.92 0.46 0.44 (0.11)
Debt/Assets
0.00% 0.00% 0.00% 0.00% 15.01% 25.01% 31.94% 41.67%
Debt/Equity
— 0.00 0.00 0.00 0.20 0.36 0.50 0.74
Asset Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
— 0.81 0.78 0.78 0.81 0.53 0.75 0.51
Capex/Depreciation
— (10.50) (198.50) (21.01) (3.88) (4.34) 0.00 0.00
Interest Coverage
— (96.84) (480.63) — (120.26) (30.56) (8.18) (13.48)
ROE
— 28.06% 162.35% (60.82%) (48.58%) (52.96%) (37.51%) (50.39%)
ROA
— (137.65%) (22.98%) (33.76%) (40.87%) (38.65%) (25.16%) (30.56%)
ROIC
— 0.00% 0.00% (96.17%) (80.86%) (64.02%) (33.19%) (40.13%)
Return on Tangible Assets
— (80.96%) (13.09%) (28.79%) (51.49%) (54.03%) (30.14%) (38.23%)
Average Days of Receivables
— — 0.00 — — — — —
Research and Development Expense of Revenue
— 0.00% 14,057.25% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
— 0.00% 10,422.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.05 0.03 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 0.00% 1,236.23% 0.00% 0.00% 0.00% 0.00% 0.00%
Graham Net Nets
— — (0.27) — — — — —
Graham Number
— — 229.24 — — — — —
Earnings Yield
— — (8.92%) — — — — —
Free Cash Flow Yield
— — (19.02%) — — — — —
Revenue per Share
— 0.00 0.17 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
— (8.93) (37.02) (23.05) (27.82) (12.61) (8.56) (5.49)
Capex per Share
— (0.35) (63.53) (10.91) (13.06) (3.18) 0.00 0.00
Free Cash Flow per Share
— (9.29) (100.55) (33.96) (40.88) (15.79) (8.56) (5.49)
Cash per Share
— 15.02 302.18 85.68 40.29 23.35 17.69 11.44
Shareholders Equity per Share
— (11.63) (49.50) 104.76 56.15 34.72 26.03 17.08
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— (11.63) (49.50) 104.76 56.15 34.72 26.03 17.08
Free Cash Flow
— (5.50) (80.43) (179.97) (264.75) (102.69) (55.70) (36.62)
Working Capital
— 7.87 232.86 422.66 236.59 150.20 116.57 186.59
Capital Expenditures
— (0.21) (50.82) (57.83) (84.59) (20.66) — —
Net Current Asset Value
— (7.08) (112.47) 409.24 150.86 60.96 30.34 101.77
EV/EBIT
— — 0.00 — — — — —
Capex to Sales
— 0.00 368.23 0.00 0.00 0.00 — —
Price to Operating Income
— — 0.00 — — — — —
Other line items
Depreciation/Fixed assets
— 0.11 0.00 0.02 0.11 0.03 0.03 4.24
Cash ROIC
— (274.74%) (39.80%) (17.83%) (37.99%) (22.37%) (15.10%) (13.32%)
Accounts Receivable Turnover
— — 0.00 — — — — —
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 — 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 — 0.00 0.00 — — —
Average Payables
— 2.24 2.24 4.53 3.96 1.79 0.94 0.72
Average Assets
— 4.74 164.24 464.50 546.06 403.88 294.60 233.55
Average Common Equity
— (23.25) (23.25) 257.80 459.40 294.72 197.63 141.65

Fold the line items

Columns are period end dates